Under mounting pressure in diabetes, Eli Lilly has just become the latest drugmaker to undergo a major shakeup.

There is troubling news for Pfizer and cancer med Xtandi. Pfizer and partner Astellas have given up trials of Xtandi in breast cancer.

Bharat Biotech has initiated a phase 1 trial of its Chikungunya vaccine, while Themis started a phase 2 of its own candidate.

Bayer's Nexavar has had the first-line liver cancer space to itself for years, but Eisai is doing its best to change that.

Two months after snapping up Ariad, Takeda is getting a quick return. The Ariad-developed potential blockbuster Alunbrig won FDA approval Friday.

What could China's newly proposed foreign drug policy mean for multinational pharma companies, and how will it change the world’s second-largest pharma…

Johnson & Johnson has kept a positive attitude about its blockbuster immunology drug Remicade and the biosimilar competition it’s facing.

Takeda has finished enrolling 20,100 children for a massive phase 3 dengue vaccine study.